Moderna (MRNA) Interest & Investment Income (2018 - 2026)

Moderna (MRNA) has 9 years of Interest & Investment Income data on file, last reported at $72.0 million in Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 20.0% year-over-year to $72.0 million in Q1 2026; TTM through Mar 2026 was $296.0 million, a 25.06% decrease from a year earlier, with the FY2025 full-year figure at $314.0 million, down 26.12% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $72.0 million, up from $70.0 million in the prior quarter.
• Over the last five years, Interest & Investment Income for MRNA reached as high as $120.0 million in Q1 2024 and fell as low as $15.0 million in Q1 2022.
• Historically, Interest & Investment Income has averaged $84.2 million across 5 years, with a median of $90.0 million in 2025.
• Across the five-year window, Interest & Investment Income jumped 1350.0% in 2022 and slipped 29.13% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $87.0 million in 2022, then increased by 18.39% to $103.0 million in 2023, then retreated by 11.65% to $91.0 million in 2024, then slipped by 23.08% to $70.0 million in 2025, then rose by 2.86% to $72.0 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $72.0 million in Q1 2026, $70.0 million in Q4 2025, and $73.0 million in Q3 2025.